NTLA
Intellia Therapeutics, Inc.
$16.84
-0.59 (-3.38%)
At close · Jul 8
Market Cap
$2.16B
Shares
139,722,277
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.84
Open$16.81
Day$16.35–17.09
52W$7.95–28.25
Avg vol 30d5.9M
Short int50.3M · 36.0% float · 7.5d
Short vol47%
Last earningsFeb 26, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+19%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+43%
trailing
YTD return
+87%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
7 of 308 funds reported for Jun 30 · net +60.1K sh shares · +1 new
Insider flow
Distributing
Net -$44.3K over 90 days · 100% sells
Short interest
Rising
36.01% of float · ▲ +3.7% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
308 holders — near 3-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-395.9M
Balance sheet
$155.5M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $14 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
7 of 308 funds reported for Jun 30 · net +60.1K sh shares · +1 new
Insider flow
Distributing
Net -$44.3K over 90 days · 100% sells
Short interest
Rising
36.01% of float · ▲ +3.7% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
308 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $17 · 44%
52-wk high $28
vs 200-day avg +23%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTLA
this stock
Intellia Therapeutics, Inc.
|
$2.16B | +87.3% | +16.9% | — | 36.0% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTLA | -0.5% | +24.8% | +43.4% | -0.5% | +87.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -0.3% | +24.0% | +36.0% | -0.3% | +78.0% |